FDA Delivers Another Blow to Solid Biosciences Stock

The FDA put Sold Biosciences' DMD treatment on clinical hold

by Patrick Martin

Published on Nov 12, 2019 at 9:56 AM

The worst stock on the Nasdaq this morning is Solid Biosciences Inc (NASDAQ:SLDB), down 69.2% to trade at $3.39, and earlier hitting a new record low of $3.15. This comes after a trial for the drugmaker's therapy for Duchenne muscular dystrophy was put on clinical hold by the Food and Drug Administration (FDA). This is the second time the FDA has put a hold on the treatment due to serious side effects. 

This is pacing to be SLDB's worse single-session percentage drop ever, surpassing the 67.8% bear gap from February when the FDA placed its first clinical hold. Prior to today, the shares had traded in a tight range between the $7-$12 levels for the past six months.

Despite these struggles, half of analysts remain confident in their "strong buy" ratings. But the security is certainly vulnerable to bear notes now, considering its consensus 12-month price target of $12.38 was a 10% premium to last night's closing perch at $11.

Options traders are firmly entrenched in calls, albeit amid limited absolute volume. In the last 10 days, 260 calls were bought to open at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), compared to 12 puts. However, given how short interest accounts for a healthy 12.3% of SLDB's total available float, it's possible some of these calls could be shorts seeking an options hedge against any unexpected upside. 


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Roller Coaster Week Defined by Trade Headlines, Jobs Report
The Dow made outsized moves in both directions this week
Needham is Buying Trade Desk Ahead of the 2020 Election
Trade Desk stock has more than doubled in 2019
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.